Document:

Respirics Product Development Agreement

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 
  
 Exhibit 10.11 
  
 PRODUCT DEVELOPMENT AGREEMENT 
  
 THIS PRODUCT DEVELOPMENT AGREEMENT is made and entered into this 24th day of
January, 2003 (the “Effective Date”) between Respirics, Inc., a Delaware corporation having an address at 6008 Triangle Drive, Suite 101, Raleigh, NC 27617 (hereinafter referred to as “Respirics”), and TEAMM
Pharmaceuticals, a Delaware corporation and a wholly owned subsidiary of Accentia, Inc., a Florida corporation, having a primary address at 3000 Aerial Center Parkway, Suite 110, Morrisville, North Carolina 27560 (“TEAMM”). 

 
 WITNESSETH 
  
 WHEREAS, Respirics has exclusive rights to, and is currently
developing, the MD-TurboTM inhaled drug delivery
device, as described in the patents and patent applications listed on Exhibit A attached hereto and incorporated herein by reference (the “Product”); 
  
 WHEREAS, TEAMM wishes to fund the further development of the Product in order to enable its approval by the U.S. Food
and Drug Administration (“FDA”), in exchange for Respirics entering into an exclusive distribution arrangement with TEAMM for the sale of Products in the United States; and 
  
 WHEREAS, Respirics wishes to accept such funding on the terms described herein and enter into such an arrangement
with TEAMM. 
  
 NOW, THEREFORE, for and in consideration of
the covenants, conditions, and undertakings hereinafter set forth, it is agreed by and between the parries as fellows: 
  
 1. Definitions 
  
 For purposes of this Agreement, and in addition to those terms defined elsewhere in this Agreement, the following terms shall have the meanings set forth
below unless the context dictates otherwise. 
  
 1.1 “Confidential Information” means all proprietary or confidential information of Respirics, including all information concerning the Product, Product Improvements (as defined below), or Product Know-How (as defined below), any
data derived there from, or any other trade secrets, information, technical data, know-how, and other confidential and proprietary information, including, but not limited to, that which relates to research, products, services, customers, markets,
software, product plans, protocols, methods, developments, inventions (whether patentable or not), chemical compounds, mixtures, formulas, formulations, manufacturing processes, strategies, processes, designs, drawings, engineering information,
marketing or finances. Specifically excluded from “Confidential Information” shall be information which: (a) is or becomes part of the public domain, through no fault of either party; (b) is lawfully disclosed without limitation to TEAMM
by a third party who is not obligated to retain such information in confidence; or (c) is required to be disclosed by law, regulation, or order of a court or other tribunal of 

  

 
competent jurisdiction, provided that TEAMM provides Respirics with (i) prior written notice of such proposed disclosure, in order to allow Respirics to take
reasonable and lawful actions to avoid and/or minimize the extent of such disclosure and (ii) reasonable assistance in minimizing the extent of such disclosures, as requested by Respirics. 
  
 1.2 “Product Improvements” shall
mean any inventions, discoveries, information, knowledge, improvements or modifications related to the practice of the Product which come into the possession of Respirics during the term of this Agreement. 
  
 1.3 “Product Know-How” shall mean any research and
development information, un-patented inventions, preclinical and/or clinical data, technical data, or knowledge related to the practice of the Product or Product Improvements in the possession of or which comes into the possession of Respirics.

  
 1.4 For the purposes of this agreement,
“TEAMM” shall mean Teamm Pharmaceuticals, Inc., a wholly-owned subsidiary of Accentia, Inc., a Florida corporation, Biotech Specialty Partners, IXC, or other subsidiaries or affiliates of Accentia, Inc. 
  
 2. Development Program. 
  
 2.1 Conduct of Research. Research shall use
commercially reasonable efforts to perform the Development Program as set forth in Exhibit B, attached hereto and incorporated herein by reference (the “Development Program”), according to the specifications and schedule set forth
therein. 
  
 2.2 Compliance. The
Development Program shall be performed by Respirics in accordance with all applicable laws, rules, and regulations. 
  
 2.3 Funding. TEAMM shall pay Respirics a total of $1,070,000, in accordance with the budget and payment schedule attached hereto as
Exhibit C, attached hereto and incorporated herein by reference, for the conduct of the Development Program, provided that, in the event TEAMM fails to provide funding on the terms required by this Agreement, TEAMM shall, in addition to any
other remedies available to Respirics, be liable to Respirics for any unpaid amounts. Payments are to be made within ten (10) days of receipt of an invoice for the initiation of each Phase of the Development Program (each, a “Phase”) prior
to the beginning of such Phase. Respirics shall not commence work on a particular Phase until the funding for such Phase has been received by Respirics, and Respirics shall not be responsible or liable for any delays in performing the Development
Program caused by delays in payment by TEAMM. 
  
 2.4 Development Reporting. During the term of this Agreement, Respirics shall (i) provide monthly status reports via teleconference with TEAMM regarding Respirics’ 

  

 
progress with respect to the Development Program and (ii) furnish written reports regarding the progress of the Development Program within thirty (30) days
of the completion of each Phase of the Development Program. A final written report setting forth the results of the Development Program shall be prepared by Respirics and submitted to TEAMM within thirty (30) days following the sooner of (i)
completion of the Development Program or (ii) the effective date of any early termination pursuant to Section 5. In addition, during Phases TV and V of the Development Program, Respirics shall keep TEAMM periodically informed as to the progress of
the regulatory approval process with respect to the Product, and, to the extent reasonably possible, shall provide TEAMM with advance notice of any pending approval in order to provide sufficient time to prepare for the initiation of TEAMM’s
marketing and sales efforts pursuant to the Distribution Agreement (as defined below). 
  
 2.5 Intellectual Property Rights. All Products, Product Improvements, Product Know-How, all intellectual property rights related to
Products, Product Improvements, and Product Know-How, regulatory approvals, and related rights and/or documentation shall be the property of Respirics. TEAMM shall not acquire any rights of any kind whatsoever with respect to the Product, Product
Improvements, or Product Know- How. Respirics shall have complete, sole, and unfettered discretion regarding all matters related to the development, regulatory approval, and protection of all technology and rights thereto with respect to the Product
and Product Improvements. 
  
 2.6
Warrants. If TEAMM provides all funding to Respirics required by this Agreement on or before the required due dates, but Respirics does not obtain final EDA clearance and approval of a 510(k) submission made with respect to the Product by
January 24, 2005, Respirics shall issue TEAMM a warrant to purchase 164,249 shares of Common Stock of Respirics, exercisable at $1.00 per share, in the form set forth at Exhibit D hereof, provided that Respirics shall have no such obligation
if (i) it has submitted a 510(k) application to FDA by July 24, 2004, (ii) such failure to obtain regulatory approval results from circumstances beyond Respirics’ reasonable control, or (iii) TEAMM has not provided funding on or before each
specified funding date. 
  
 If, prior to
Respirics receiving all funding from TEAMM, as required by this Agreement, (i) the parties mutually agree to terminate this Agreement due to a reasonable expectation that final FDA clearance and approval of a 510(k) submission made with respect to
the Product will not be obtained by January 24, 2005 or (ii) TEAMM terminates this Agreement pursuant to Section 5.2(c) in conjunction with a reasonable expectation that final FDA clearance and approval of a 510(k) submission made with
respect to the Product will not be obtained by January 24, 2005, Respirics shall issue TEAMM a warrant to purchase shares of Common Stock of Respirics, exercisable at $1.00 per share, in the form set forth at Exhibit C hereof, in the
amounts described in the table below, provided that Respirics shall have no such obligation if (i) such expectation results from circumstances beyond Respirics’ reasonable control or (ii) TEAMM has not provided funding on or before each
specified funding date. 
  

			
	 Total Funding Provided to Respirics
 by TEAMM/Hopkins

	  	 Number of Shares For Which
 Warrant May Be Exercised

	$0	  	0
	$200,000	  	30,701
	$550,000	  	84,427
	$950,000	  	145,829

  
 In
any event, any warrant issued pursuant to this Section 2.6 shall be considered liquidated damages, and TEAMM’s sole and exclusive remedy, with respect to any failure by Respirics to complete the Development Program in a timely fashion pursuant
to the terms of this Agreement. 
  
 3. Distribution
Agreement. Upon execution of this Agreement by all three parties, Respirics shall enter into a Distribution Agreement with TEAMM, in the form attached hereto as Exhibit E (the “Distribution Agreement”), providing the terms and
conditions upon which TEAMM shall market and sell Products on behalf of Respirics. The Distribution Agreement shall only become effective and binding upon Respirics’ successful completion of the Development Program within its prescribed budget
and schedule, as defined in this Agreement, and final clearance and approval by the FDA of Respirics’ 510(k) submission with respect to the Product. 
  
 4. Confidential Information. TEAMM shall keep in strict confidence, using commercially reasonable measures at least as strict as applies to their
own proprietary and/or confidential information of a similar nature, and not disclose or make available to third parties, nor make any use of, Confidential Information except (i) with the prior written consent of Respirics or (ii) for purposes of
preparing to perform or performing under the Distribution Agreement. The parties recognize and agree that remedies at law for breach of the provisions of this Section 4 may be inadequate and Respirics, shall, in addition to any other rights, which
it might have, be entitled to seek injunctive relief. The obligations of this paragraph shall survive termination of this Agreement. 
  
 5. Term and Termination. 
  
 5.1 Unless terminated earlier in accordance with Sections 5.2 or 5.3 below, this Agreement shall terminate on the completion of the
Development Program. 
  
 5.2 Without prejudice to
any other rights it may have hereunder or at law or in equity, TEAMM may terminate this Agreement immediately by written notice to Respirics upon the occurrence of any of the following: 
  

	 	(a)	Respirics becomes insolvent, an order for relief is entered against Respirics under any bankruptcy or insolvency laws or laws of similar import; 

  

	 	(b)	Respirics makes an assignment for the benefit of its creditors or a receiver or custodian is appointed for it or its business is placed under attachment, garnishment or other
process involving a significant portion of its business; or 

  

	 	(c)	after thirty (30) days’ written notice from the terminating party without cure by Respirics of any material breach of this Agreement by Respirics. 

  
 5.3 Without prejudice to any other rights it may have
hereunder or at law or in equity, Respirics may terminate this Agreement, the Distribution Agreement, and/or the exclusivity of the Distribution Agreement, as determined by Respirics in its sole discretion, immediately by written notice to TEAMM
upon the occurrence of any of the following: 
  

	 	(a)	TEAMM becomes insolvent, an order for relief is entered against TEAMM under any bankruptcy or insolvency laws or laws of similar import; 

  

	 	(b)	TEAMM makes an assignment for the benefit of its creditors or a receiver or custodian is appointed for it or its business is placed under attachment, garnishment or other process
involving a significant portion of its business; 

  

	 	(c)	after thirty (30) days’ written notice from Respirics without cure by TEAMM of any material breach of this Agreement by TEAMM 

  

	 	(d)	TEAMM fails to provide funding when due as required by Section 2.3. 

  
 5.4 Any termination under any provision of this Agreement shall not relieve TEAMM of its obligation to pay any amounts due or owing at the
time of such cancellation or termination. 
  
 5.5
Upon the termination of this Agreement pursuant to Sections 5.2 or 5.3, TEAMM shall immediately return all Confidential Information, reports provided pursuant to Section 2.4, any other documents provided to TEAMM, and any copies of the foregoing to
Respirics. 
  
 6. Use of Respirics’ Name. The use of
the name of Respirics, or any contraction thereof, in any manner in connection with the exercise of this Agreement is expressly prohibited except with prior written consent of Respirics. The foregoing notwithstanding, TEAMM shall have the right to
identify Respirics and to disclose the terms of this Agreement in any prospectus, offering memorandum, or other document or filing required by applicable securities laws or other applicable law or regulation. 
  

 7. Waiver. It is agreed that no waiver by either party hereto of any breach or default of any of
the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent and/or similar breach or default. 
  
 8. Assignment. This Agreement is binding upon and shall inure to the benefit of Respirics and TEAMM, and their successors and assigns. This
Agreement shall not be assignable or otherwise transferable by either party without the prior written consent of the other, which consent shall not be unreasonably withheld, except that Respirics may assign or otherwise transfer its rights under
this Agreement to the following parties without obtaining consent: (1) a successor to Respirics’ business, or a successor to that portion of Respirics’ business that pertains to the Product, and (2) any entities controlled by, controlling,
or under common control with Respirics. 
  
 9. Independent
Contractor Status. Respirics, for all purposes related to this Agreement, shall be deemed an independent contractor of TEAMM, and nothing in this Agreement shall be deemed to create a relationship of employment or agency or to constitute the
parties as partners or joint venture partners. 
  
 10.
Notices. Any notice required or permitted to be given to the parties hereto shall be deemed to have been properly given when received by means of confirmed facsimile transmission, recognized national overnight courier, or first-class
certified mail to the other party at the appropriate address or facsimile number as set forth below or to such other addresses or facsimile numbers as may be designated in writing by the parties from time to time during the term of this Agreement

  
 TEAMM 
  
 TEAMM Pharmaceuticals, Inc. 
 3000 Aerial Center Parkway, Suite 110 
 Morrisville, North Carolina 27560 
 Attn: President 
 Fax: 919 481 9300 
  
 Respirics 
  
 Respirics, Inc. 

6008 Triangle Drive Suite 101 
 Raleigh NC
27617 
 Attn: President 
 Fax:
919 789 4254 
  
 11. Governing Law: Jurisdiction. This
Agreement shall be governed by and construed and enforced in accordance with the laws of the State of North Carolina, excluding that body of law known as choice of law, and shall be binding upon the parties hereto in the 

  

 
United States and worldwide. All disputes with respect to this Agreement shall be brought and heard either in the North Carolina state courts located in Wake
County, North Carolina, or the federal district court for the Eastern District of North Carolina located in Raleigh, North Carolina. The parties to this Agreement each consent to the jurisdiction and venue of such courts. The parties agree that
service of process upon them in any such action may be made if delivered in person, by courier service, by telegram, by telefacsimile or by first class mail, and shall be deemed effectively given upon receipt. 
  
 12. Complete Agreement. This Agreement and the Exhibits hereto
(including the Distribution Agreement) contain the entire agreement between the parties. No amendments or modifications to this Agreement shall be effective unless made in writing and signed by authorized representatives of both parties. 

 
 13. Force Majeure. Neither party will be responsible for delays
resulting from acts beyond the reasonable control of such party, provided that the non-performing party uses reasonable commercial efforts to avoid or remove such causes of nonperformance and continues performance hereunder with reasonable dispatch
whenever such causes are removed. 
  
 14. Survival of
Terms. Sections 1,2.5, and 4-14 shall survive the expiration or termination of this Agreement. 
  
 [Signature page to follow.] 
  

 IN WITNESS WHEREOF, TEAMM Pharmaceuticals, Inc., and Respirics have executed this Agreement, by their
respective officers hereunto duly authorized, the day and year first above written. 
  

									
	TEAMM PHARMACEUTICALS, INC.	 	 	 	Respirics, Inc.
					
	 By:
	 	 /s/ Martin G. Baum
	 	 	 	 By:
	 	 /s/ Gilbert S. Mott, Jr.

	 	 	 Martin G. Baum
	 	 	 	 	 	 Gilbert S. Mott, Jr.

	 	 	 President and CEO
	 	 	 	 	 	 President and CEO

  

  
 EXHIBIT A 

 
 PRODUCT PATENTS 
  

			
	 Title

	  	 Serial Numbers and Dates

	Device For Use With Metered Dose-Inhalers (MDIs)	  	 Patent No. 5,826,571
 Patent Issued: October 27,
1998

		
	Device For Use With Metered Dose Inhalers (MDIs)	  	 Patent No. 6,357,442
 Patent Issued: March 19,
2002

		
	 Inhalation Actuated Device For Use With Metered
 Dose
Inhalators (MDIs)
	  	 Patent Pending
 Serial No. 09/535,097
 Filed March 24, 2000

		
	 Inhalation Actuated Device For Use With Metered
 Dose
Inhalators (MDIs)
	  	 Patent Pending
 Serial No. 10/074,27 1
 Filed February 11, 2002

  

  
 EXHIBIT B 

 
 DEVELOPMENT PROGRAM 
  
 BACKGROUND 
  
 The MD (metered dose) Turbo device market advantage is that a multiplicity of currently approved ethical and generic metered dose inhalers
(“MDIs”) can be inserted in the device and be breath activated. This will be the only low-cost device that offers this capability when commercialized. Most importantly, the breath-triggering mechanism offers a significant market advantage
over the use of standard MDIs since it eliminates the coordination issue experienced by patient’s when they attempt to coordinate inhalation and pressing of the MDI canister. It has been reported in the literature that 50-70% of the patients
are unable to coordinate their inhalation with “firing” of the MDI canister. As a result, the MD TurboTM was developed to eliminate the issue of patients being unable to coordinate this activity. 
  
 Respirics’ MD Turbo possesses the following features: 
  

	 	(1)	a breath-actuated triggering mechanism (set at a pre-determined inspiratory air flow rate, typically 30-60L/min) which automatically depresses the MDI canister for release of a
dose; 

  

	 	(2)	the ability to incorporate a multiplicity of commercially available innovator or generic MDI products, representing approximately 80 % of the medications currently used to
treat asthma; 

  

	 	(3)	the ability to accept replacement MDI products. The device is anticipated to be reusable for at least one year, e.g., Ventolin canister of 200 doses with one can used per month,
i.e., 2400 delivered doses; 

  

	 	(4)	an electronic dose-counting mechanism for tracking the number of doses used from the MDI canister; i.e., a countdown of doses available; and 

  

	 	(5)	a mechanical override button which automatically depresses the MDI canister for release of a dose as the patient inhales, i.e., only for those patients (young children less than 6
years of age, elderly or very severe asthmatic) who may have difficulty achieving the required inspiratory effort necessary to automatically trigger firing of the device. 

  
 In addition to the above features, the MD Turbo is patent protected. There are two issued United States patents, one issued Canadian patent,
and one issued Australian patent on the MD Turbo device. Additional CIPs are pending and foreign patent filings have been initiated covering the seventeen EPO States, Japan, Australia and Canada. All of these patents are either owned or exclusively
licensed by Respirics. 
  

  
 Objectives 

 
 The following objectives (within each defined phase of the Development Program’s
research activities) have been established for the MD Turbo development program: 
  

	 	(1)	Phase I - to finalize the design of the MD Turbo device; to prepare SLA prototype models of this design; and, to perform preliminary in vitro experiments with the prototype
model 

  

	 	(2)	Phase II - to obtain single cavity tooling and stamping of the components for the MD Turbo device; and, to perform preliminary in vitro tests with the injection molded and
stamped assembled components 

  

	 	(3)	Phase III - to manufacture sufficient devices to complete the 510(k) in vitro testing program; and, to perform a failure effect and mode analysis (FEMA) on assembled
MD Turbo devices 

  

	 	(4)	Phase IV - to collate the results obtained in the 510(k) testing program and to prepare the 510(k) application for submission to the FDA 

  

	 	(5)	Phase V - FDA review of 510(k) pre-market notification application 

  
 Each of the above phases is briefly described below as to the research activities that will be performed: 
  
 PHASE I 
  
 During this phase of the program, the MD Turbo design will be finalized. The exterior of the device will be modified to provide a more ergonomic presentation. After the
design is “locked-in”, stereo lithography will be used to produce plastic components and “working” models will be constructed and subjected to a battery of laboratory tests to verify the performance of the models using currently
marketed MDIs. Any final adjustments in the MD Turbo will be made at this time. The final design will be subject to approval by TEAMM, which approval shall not be unreasonably withheld. 
  
 PHASE II 
  

Following completion of Phase I, the engineering design files will be provided to a qualified injection molding facility, single-cavity molds will be designed and
fabricated for all plastic components, and the molds will be qualified for production. Plastic components will then be produced from these molds. 
  
 Metal stamped and machined parts will also be fabricated during this phase and these components, along with the molded plastic components, will be used to assemble
working devices. 
  
 The final task in Phase II will be to perform laboratory
testing on these working devices to verify drug delivery performance prior to initiating Phase III. 
  

 PHASE III 
  
 During this phase, Respirics will manufacture and assemble a reasonably sufficient number of devices (estimated to be 25-50 devices) to
complete the 510(k) testing program. The 510(k) testing program will entail the comparison of the MD Turbo device to (1) the standard MDI and (2) a predicate device (spacer), using a minimum of three drug products. Presently, Respirics plans to use
those products that are generating the most revenues in the open market, i.e., Serevent®, Flovent®,
Ventolin® (both HFA and CFC products),
Combivent®, Atrovent® and several generic CFC MDI products. Some of the 510 (k) tests that will need to be performed include emitted dose delivery, dose through canister life, shot weight, particle/droplet
sizing, cascade impaction, spray pattern, and plume geometry. Respirics plans to confirm the required tests with the FDA prior to conducting these studies. 
  
 PHASE IV 
  
 During this phase, the data generated in the 510(k) testing will be collated into the correct format for submission of the 510(k) application. Respirics anticipates using
an outside consultant to facilitate this activity. 
  
 PHASE V 
  
 There are no research activities planned during this
phase as the FDA is reviewing the 510(k) submission. However, there will need to be planning and activities performed during this phase so that an orderly launch of the product can take place. These activities should be discussed as we enter Phase
TV so that we have sufficient time and resources to plan the potential launch. 
  
 Respirics shall use commercially reasonable efforts to complete the Development Program within eighteen (18) months following execution of the Development Agreement, according to the schedule established on Exhibit C, provided that,
if Respirics has submitted a 510(k) application within eighteen (18) months of the Effective Date, Respirics’ shall have satisfied its obligation to exercise commercially reasonable efforts to complete the Development Program. 
  
 Deliverables 
  
 The Respirics deliverables will include monthly teleconferences on the status of the research activities plus a summary report upon
completion of each phase of the program. The summary reports will be due thirty (30) days after completion of the research activities for each phase as outlined in the Development Program. 
  

  
 EXHIBIT C 

 
 DEVELOPMENT BUDGET AND PAYMENT SCHEDULE 
  

							
	 PHASE

	  	COST

	 	 	ESTIMATED
TIME

	 I. Finalize design; create SLA prototype models; perform preliminary testing with the SLA prototype model
	  	$	[	*]	 	[*]
			
	 II. Mold tooling and stamping; limited device assembly; and preliminary in vitro testing on the assembled devices
	  	$	[	*]	 	[*]
			
	 III. Manufacture of MD Turbo devices for 510(k) testing; perform 510(k) in vitro tests; device FEMA analysis
	  	$	[	*]	 	[*]
			
	 IV. Preparation of 510(k) application for FDA submission
	  	$	[	*]	 	[*]
			
	 V. FDA review of 510(k) application
	  	$	[	*]	 	[*]
	 	  	
	
	
	 	

			
	 TOTAL COSTS
	  	 	[	*]	 	[*]
	 	  	
	
	
	 	

  
 The total payments for the Development
Program are $[*]. Payments are to be made within ten (10) days of receipt of an invoice for the initiation of each Phase prior to the beginning of such Phase; Respirics shall not commence work on a particular development Phase until the funding
for such Phase has been received by Respirics, and shall not be responsible or liable for any delays in performing caused by delays in payment by TEAMM. The amount for each phase is as follows: 
  
 Phase I = $[*] 
 Phase II = $[*] 
 Phase III = $[*] 
 Phase IV = $[*] 
 Phase V = $[*] 
  

  
 EXHIBIT D 

 
 FORM OF WARRANT 
  

  
 EXHIBIT E 

 
 DISTRIBUTION AGREEMENT 
  

 15Mikart Mfg and Supply Agreement

  
 [*] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 
  
 Exhibit 10.13 
  
 MANUFACTURING AND SUPPLY AGREEMENT 
  
 THIS MANUFACTURING AND SUPPLY AGREEMENT (the “Agreement”) is
made and entered into this 6 day of June, 2003 (the “Effective Date”), by and between TEAMM PHARMACEUTICALS, INC. (“TEAMM”) and MIKART, INC. (“Mikart”). Mikart is a Georgia corporation with its
principal place of business at 1750 Chattahoochee Avenue, Atlanta, Georgia 30318. TEAMM is a Florida corporation with its principal place of business at 3000 Aerial Center Parkway, Suite 110, Morrisville, North Carolina 27560. 
  
 BACKGROUND: 
  
 Subject to the terms and conditions contained in this Agreement, TEAMM
desires to engage Mikart to manufacture the “Products” (as hereinafter defined) for commercial distribution by TEAMM, and Mikart desires to accept such appointment. 
  
 NOW, THEREFORE, FOR AND IN CONSIDERATION of the premise, Ten Dollars ($10.00) in hand paid, the mutual promises,
covenants and agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
  
 ARTICLE 1  
 DEFINITIONS 
  
 The following words, terms and phrases, when used herein, shall have the following respective meanings: 
  
 1.1 “Batch” shall mean the quantity of 1,100,000 tablets of
the Products. 
  
 1.2 “Contract Year” shall mean
a twelve (12) consecutive month period after the Qualification Date and during the Term of this Agreement. The first Contract Year shall commence as of the Qualification Date, and subsequent Contract Years shall commence on each anniversary of the
Qualification Date. 
  
 1.3 “FDA” shall mean the
United States Food and Drug Administration or any successor agency thereof. 
  
 1.4 “Health Registrations” shall mean the Abbreviated New Drug Application issued by the FDA with respect to the Products and any other governmental or regulatory consents, registrations, approvals or
permits necessary to sell or manufacture the Products in the Territory or elsewhere as may become necessary in accordance with Section 2.4 hereof. 
  
 1.5 “Products” shall mean [*] 
  

 1.6 “Qualification Date” shall mean the date on which Mikart satisfactorily completes
its validation and testing pursuant to Article 2 of this Agreement such that it becomes authorized to begin manufacturing the Products under the Health Registrations in accordance with the terms of this Agreement. 
  
 1.7 “Specifications” shall mean the specifications for the
manufacturing, packaging and labeling of the Products described on Exhibit A attached hereto and incorporated herein by reference. 
  
 1.8 “Territory” shall mean the United States of America and its territories and such other locations as may be designated by the parties
hereto pursuant to Section 2.4. 
  
 ARTICLE 2 
 VALIDATION, TESTING AND HEALTH REGISTRATIONS 
  
 2.1 Validation. TEAMM and Mikart acknowledge and agree that Mikart must validate three (3) Batches of the Products prior to
selling any of the Products to TEAMM. Mikart shall conduct such validation on three (3) Batches of the Products and, thereafter, TEAMM shall be obligated to purchase such Batches in accordance with the terms of this Agreement. Such Batches shall be
a part of, and shall be applied to, TEAMM’s minimum purchase requirements within the first Contract Year. 
  
 2.2 Testing. Upon its successful completion of the validations described in Section 2.1, Mikart shall conduct stability testing on
the Products as required by federal law. All of Mikart’s costs incurred in connection therewith shall be periodically billed to and paid by TEAMM on a quarterly basis. 
  
 2.3 Health Registrations. Mikart shall own the Health Registrations in its own name and shall
maintain the same in full force and effect at all times during the Term of this Agreement. 
  
 2.4 Additional Locations. In the event TEAMM desires to market, distribute or sell the Products in any location not set forth
in Section 1.8 (or previously designated pursuant to this Section 2.4), then Mikart shall, at TEAMM’s request, cooperate in good faith with TEAMM to obtain any Health Registrations necessary or appropriate therefore (and TEAMM shall pay all of
Mikart’s reasonable out-of-pocket expenses therefore); provided, however, TEAMM shall not market, distribute or sell any Products in such locations unless and until such Health Registrations are obtained. 
  

 -2- 

  
 ARTICLE 3 

 MANUFACTURE 
  
 3.1 Exclusivity. Subject to the terms and conditions contained herein, Mikart shall not manufacture, package or sell any
product with an identical formulation to the Products for any person or entity other than TEAMM from and after the Qualification Date and throughout the remainder of the Term of this Agreement (the “Manufacturing Period”), and TEAMM shall
purchase exclusively from Mikart all of TEAMM’s requirements of the Products during the Term of this Agreement. TEAMM hereby agrees that, in the event it desires to enhance, extend or otherwise modify the Products during the Term of this
Agreement, it shall offer the right of first refusal to Mikart to be the sole manufacturer thereof (on commercial terms other than price substantially similar to those contained herein). Nothing contained herein shall be deemed in any way to
preclude Mikart from manufacturing, packaging or selling any products on behalf of any person or entity where the formulation for such products differs from the formulation for the Products. During the Term of this Agreement, Mikart shall not sell
or transfer the Products to any third party without written consent of TEAMM. 
  
 3.2 Limited Warranties. Mikart hereby represents and warrants to TEAMM that the Products when manufactured and sold to TEAMM hereunder shall conform to the Specifications. In addition,
Mikart represents and warrants to TEAMM that Mikart, in its manufacture of the Products, shall comply with all applicable federal, state and local laws, rules and regulations in the Territory, including without limitation the current Good
Manufacturing Practices as published and amended from time to time by the FDA, and Mikart’s manufacturing and storage facilities shall comply with all applicable federal, state and local laws, rules and regulations in the Territory. EXCEPT
AS SET FORTH IN THIS SECTION 3.2 AND SECTION 9.1, MIKART MAKES NO OTHER REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND MIKART HEREBY SPECIFICALLY DISCLAIMS ALL SUCH OTHER REPRESENTATIONS AND WARRANTIES, INCLUDING, WITHOUT LIMITATION, THE
IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. With respect to each Batch of the Products manufactured hereunder, this Section 3.2 shall remain effective until the expiration date noted on such Products.

  
 3.3 Quality Control.

  
 (a) Mikart shall perform quality control
testing on the Products in accordance with normal industry standards to determine whether such Products conform to the Specifications. Contemporaneously with each shipment of Products hereunder, Mikart shall provide TEAMM with a certificate of
analysis with respect to such Products. In addition, Mikart shall perform, at TEAMM’s expense, any and all other testing relating to the Products which is reasonably requested by TEAMM to confirm that such Products meet the Specifications and
promptly provide TEAMM with the results thereof. 
  

 -3- 

 (b) In addition, Mikart shall be responsible for conducting an ongoing stability program
for the Products as required by federal law. 
  
 (c) Mikart shall, upon the reasonable request of TEAMM, assay any Products returned to TEAMM by a third party purchaser. TEAMM shall reimburse Mikart for the costs of any such assay unless the results thereof prove the cause of return is as
a result of Mikart’s negligence or willful misconduct or the failure of such Products to comply with the limited warranties contained in Section 3.2 hereof. 
  
 (d) In the event that any Batch is subject to a recall, TEAMM, at its expense, shall conduct the recall,
except that Mikart shall reimburse TEAMM for the costs of such recall (including reimbursing TEAMM for the Products at the invoice prices paid by TEAMM therefore) in the Territory to the extent such recall results from the failure of the Products to
comply with the limited warranties contained in Section 3.2 hereof. 
  
 (e) Each party hereto shall promptly notify the other of any recall of Products which has been directed by it or by any governmental or regulatory entity or agency for any reason whatsoever. Such notice shall identify
the reason for the recall and all relevant details thereof. 
  
 (f) Each party hereto shall promptly deliver to the other a copy of all notices received by it from the FDA during the Term of this Agreement relating to the manufacture, packaging, storage or sale of the Products.

  
 (g) Upon the reasonable advance request of
TEAMM, Mikart shall permit a representative of TEAMM to inspect its facilities where the Products are manufactured, packaged and stored, provided such representative first executes a copy of Mikart’s standard visitor confidentiality agreement.

  
 3.4 Packaging and Labeling Materials. Mikart
shall order from time to time, at TEAMM’s request and expense, labels, package inserts and other packaging materials (the “Labeling Materials”) in sufficient quantities to permit the packaging of the Products ordered by TEAMM from
time to time hereunder. 
  
 ARTICLE 4 
 ORDERS AND SALES 
  
 4.1 Forecasts. Commencing on the Qualification Date, and thereafter at least thirty (30) days prior to the commencement of
each calendar quarter, TEAMM shall provide Mikart with a non-binding, rolling twelve (12) month forecast of its requirements for the Products. 
  
 4.2 Purchase Orders. TEAMM shall place its orders for the Products no later than ninety (90) days prior to the requested
delivery date using separately numbered, written purchase orders. Each purchase order must be for one or more full Batches (provided TEAMM 

  

 -4- 

 
shall have the right to specify the size packaging requirements of each order from among 100 or 500 tablet bottles and any other package sizes agreed to by
the parties hereto). Purchase orders shall be transmitted to Mikart via U.S. mail, private courier, or facsimile transmission. Each purchase order shall include complete and accurate information with respect to the requested Products, quantity,
sizes, shipment dates, and shipment method and delivery destination. Subject to this Section 4.2, Mikart shall ship Products within five (5) days after the requested shipment date in the corresponding purchase order. Mikart shall promptly notify
TEAMM upon its receipt of any purchase orders containing shipment dates which need to be rescheduled, and Mikart and TEAMM shall work together in good faith to schedule a new shipment date for such order (which shall not be later than thirty (30)
days after the date requested by TEAMM). In addition, TEAMM may postpone a requested shipment date by providing Mikart at least sixty (60) days prior written notice thereof. 
  
 4.3 Minimum Purchase. During each Contract Year, TEAMM shall purchase from Mikart the following minimum amount
of Products: 
  

			
	 Contract Year

	 	 Minimum Amount

	 1
	 	[*] 100 tablet bottles
	 2
	 	[*] 100 tablet bottles
	 3
	 	[*] 100 tablet bottles
	 4
	 	[*] 100 tablet bottles
	 5
	 	[*]0 tablet bottles

  
 ARTICLE 5

 PRICES, TERMS OF PAYMENT 
  
 5.1 Price. The prices to be paid for the Products by TEAMM to Mikart for shipments made during the first year after the Effective Date shall
be as follows: 
  

				
	Price

	  	 Size

	$	[*]	  	Sample 1’s
	$	[*]	  	100 tablet bottles
	$	[*]	  	500 tablet bottles

  
 5.2 Price
Adjustments. Mikart shall have the right to increase the prices charged for the Products pursuant to Section 5.1 hereof during each year after the Effective Date to reflect any increase in the costs of goods or services necessary to
manufacture the Products (“Total Product Costs”). Mikart shall use its reasonable efforts to prevent any such cost increases from occurring. In the event that Mikart seeks to increase the prices charged for the Products pursuant to Section
5.1 hereof by more than five percent (5%) during any one (1) year after the Effective Date to reflect an increase in Total Product Costs, Mikart shall provide written notice to 

  

 -5- 

 
TEAMM explaining the reason(s) for such additional price increase prior to any price increase becoming effective. 
  
 5.3 Payment Terms. Mikart shall invoice TEAMM for the price of
the Products sold at the time of shipment, and TEAMM shall pay each such invoice within thirty (30) days after its receipt thereof. 
  
 ARTICLE 6 
 SHIPPING DEFECTS,
RETURNS 
  
 6.1 Shipping. Mikart shall ship
all Products ordered hereunder to TEAMM f.o.b. Mikart’s manufacturing facility, at which point title and the risk of loss for such Products shall pass to TEAMM. Mikart shall ship the Products to the location designated by TEAMM on its purchase
order. The parties agree that the method and route of shipment are at Mikart’s discretion unless TEAMM furnishes Mikart explicit instructions with the purchase order. TEAMM agrees to pay all costs of shipping and any costs of freight insurance
obtained by Mikart at the request of TEAMM. Mikart agrees to provide reasonable support to assist TEAMM in pursuing any claims it may have against carriers. 
  
 6.2 Notification of Defects. TEAMM shall notify Mikart in writing as soon as reasonably practicable after delivery to TEAMM of any
non-conforming Products containing obvious defects in such Products discoverable without affecting the integrity of such Product’s packaging (but in any event within twenty (20) days after delivery) and within thirty (30) days of the earlier of
its discovery or its notification by a third party of any latent defects. TEAMM shall be responsible for its costs to inspect all Products. 
  
 6.3 Returns. Mikart shall accept for return and replacement or credit (at invoiced cost) any Products sold to TEAMM under this Agreement
which does not conform with the limited warranties set forth in Section 3.2 and for which proper notice has been given in accordance with Section 6.2, provided TEAMM obtains prior shipping authorization from Mikart. All returns of Products with
obvious defects must be in the original manufactured condition. Mikart shall pay reasonable return freight and shipping charges. 
  
 ARTICLE 7 
 TERM AND TERMINATION

  
 7.1 Term. Unless earlier terminated in
accordance with the provisions hereof, the Term of this Agreement shall commence on the Effective Date and shall thereafter continue in effect until the fifth (5th) anniversary of the Qualification Date (the “Initial Term”). At the end of
the Initial Term and each subsequent “Renewal Term” (as hereinafter defined), the Term of this Agreement shall be automatically renewed and extended for a one (1) year period (a “Renewal Term”), unless either party delivers a
written termination notice to the other party at least six (6) months prior to the end of the Initial Term or the then current Renewal Term, as the 

  

 -6- 

 
case may be. For purposes hereof the Initial Term and any Renewal Terms are sometimes referred to collectively herein as the “Term.” 
  
 7.2 Termination. Either party may terminate this Agreement on
written notice to the other party, effective immediately if: 
  
 (a) the other party commits a material breach of any of its obligations hereunder which is not cured within sixty (60) days of written notice from the other party specifying the breach; 
  
 (b) the other party is dissolved or liquidated, files or has
filed against it a petition under any bankruptcy or insolvency law, makes an assignment to the benefit of its creditors, has a receiver appointed for all or substantially all of its property, or has a petition under any bankruptcy or insolvency law
filed against it which is not dismissed within sixty (60) days; or 
  
 (c) the Qualification Date has not occurred within two (2) years after the Effective Date. 
  
 Such right of termination shall be in addition to any other remedy a non-defaulting party may have at law or in equity due to the other party’s breach of is
obligations hereunder. 
  
 7.3 Post-Termination
Restrictions. Upon any expiration or termination of this Agreement (other than by TEAMM pursuant to Section 7.2), TEAMM shall grant Mikart at least sixty (60) days to produce all open orders in house in accordance with the conditions
of the open orders and this Agreement. In the event TEAMM terminates this Agreement pursuant to Section 7.2, and upon the request of TEAMM, Mikart shall provide TEAMM with reasonable assistance in locating or establishing a new manufacturer for the
Products. In addition to the foregoing, in the event that TEAMM terminates this Agreement pursuant to Section 7.2(b) hereof, Mikart shall, subject to applicable law, transfer to TEAMM all of Mikart’s right, title, and interest in and to the
Health Registrations, at a price equal to the fair market value of same, as determined by an independent appraiser selected by Mikart. 
  
 7.4 Changed Circumstances. In the event that the market for the Products materially changes or either party, in good faith,
believes that a material change in such party’s circumstances beyond their control has occurred which materially affects its ability to perform its obligations pursuant to this Agreement, the parties hereto shall, in good faith, negotiate
towards mutually acceptable revisions to this Agreement to address the impact of such material changes; provided, however, the terms of this Agreement shall continue in full force and effect unless and until the parties hereto agree otherwise.
Should Mikart not be able to manufacture the product for any ninety (90) consecutive day period, Section 3.1 of this Agreement shall no longer be of any force or effect and TEAMM shall be relieved of its obligations pursuant to Section 4.3 hereof.

  

 -7- 

 7.5 Force Majeure. The failure of either of the parties hereto to perform any
obligation under this Agreement solely by reason of any cause beyond its control (and due to no fault of its own), including, without limitation, acts of God, acts of government, riots, wars, strikes and accidents in transportation, shall not be
deemed to be a breach of this Agreement; provided, however, that the party so prevented from complying herewith shall continue to take all actions within its power, including payment of outstanding invoices, to comply as fully as possible
herewith. 
  
 7.6 Special
Termination. Notwithstanding anything else contained herein to the contrary, in the event TEAMM fails in any Contract Year to meet its minimum purchase requirements set forth in Section 4.3 hereof for any reason other than a breach of
this Agreement by Mikart, then Mikart shall have the right to terminate this Agreement effective immediately by delivering written notice thereof to TEAMM. 
  
 7.7 Post-Termination Obligations. Notwithstanding anything else contained herein to the contrary,
following any termination or expiration of this Agreement: 
  
 (a) TEAMM shall purchase from Mikart (at Mikart’s cost therefore) all of Mikart’s remaining inventory of the Products; and 
  
 (b) Subject to Section 7.3 hereof, Mikart shall have no further rights to use any of the TEAMM Intellectual
Property. 
  
 ARTICLE 8 
 INDEMNIFICATION AND INSURANCE 
  
 8.1 Indemnification. Mikart hereby indemnifies and agrees to defend and hold TEAMM harmless from and against losses, claims,
damages, liabilities, costs and expenses (including, without limitation, attorneys’ fees and court costs) incurred by TEAMM as a result of any breach of this Agreement by Mikart or the failure of the Products to comply with the limited
warranties set forth in Section 3.2 hereof or Mikart’s gross negligence or willful misconduct. TEAMM hereby indemnifies and agrees to defend and hold Mikart harmless from and against losses, claims, damages, liabilities, costs and expenses
(including, without limitation, attorneys’ fees and court costs) incurred by Mikart as a result of any breach of this Agreement by TEAMM, the storage, sale or distribution of the Products by TEAMM, the provision by TEAMM of any representations,
warranties, instructions or warnings regarding the Products, their proper use or the risks or dangers associated therewith other than those set forth on the Labeling Materials supplied by Mikart, or TEAMM’s gross negligence or willful
misconduct. 
  
 8.2 Insurance. Each
party hereto shall maintain with a financially sound and reputable insurer throughout the Term of this Agreement comprehensive general liability insurance, including, without limitation, product liability insurance with liability limits of at least

  

 -8- 

 
$3,000,000 per occurrence and in the aggregate. Each party hereto shall also name the other party as an additional insured party on its policy and provide
the other party with such evidence thereof as is reasonably requested by the other party from time to time. 
  
 ARTICLE 9 
 WARRANTIES AND REPRESENTATIONS OF THE PARTIES

  
 9.1 Additional Representations and Warranties of
Mikart. Mikart hereby additionally represents and warrants to TEAMM the following: 
  
 (a) Mikart is a corporation duly organized and existing in good standing under the laws of the State of Georgia; 
  
 (b) There are no material adverse claims pending or, to the
best of Mikart’s knowledge, threatened against Mikart by any entity with respect to the Products; 
  
 (c) Mikart is neither a party to nor otherwise bound by any agreement or instrument which prohibits or prevents it from performing its
obligations under this Agreement; and 
  
 (d)
Mikart’s manufacturing, packaging and storage facilities comply in all material respects with all applicable federal, state and local laws, rules and regulations in the Territory. 
  
 9.2 Representations and Warranties of TEAMM. TEAMM hereby additionally represents and warrants to
Mikart the following: 
  
 (a) TEAMM is a
corporation duly organized and existing under the laws of the State of Florida; 
  
 (b) There are no material adverse claims pending or, to the best of TEAMM’s knowledge, threatened against TEAMM by any entity with
respect to any of its products or business; 
  
 (c) TEAMM is neither a party to nor otherwise bound by any agreement or instrument which prohibits or prevents it from performing its obligations under this Agreement; and 
  
 ARTICLE 10 
 CONFIDENTIALITY AND NONSOLICITATION OF PERSONNEL 
  
 10.1 Confidentiality. Each party hereto acknowledges that it has been and shall be exposed to certain “Confidential Information” and “Trade Secrets” (both as hereinafter defined) 

  

 -9- 

 
of the other party in connection with the transactions contemplated by this Agreement and that its unauthorized use or disclosure of such information or data
could cause immediate and irreparable harm to such other party. Accordingly, except to the extent that it is necessary to use such information or data to perform its obligations under this Agreement, neither party shall, without the express prior
written consent of the other party, redistribute, market, publish, disclose or divulge to any person or entity, or use or modify for use, directly or indirectly, in any way for any person or entity: (a) any of the other party’s Confidential
Information during the Term of this Agreement and for a period of three (3) years after any expiration or termination of this Agreement; and (b) any of the other party’s Trade Secrets at any time during which such information constitutes a
trade secret under applicable law. For purposes hereof, “Confidential Information” shall mean all competitively sensitive, non-public information (other than “Trade Secrets”) of or about a party which is not generally known by or
available to such party’s competitors, and “Trade Secrets” shall mean “Trade Secrets” as defined under applicable law. This Section 10.1 supersedes and replaces any prior confidentiality agreements between the parties, all
of which are hereby terminated, and each of which shall hereafter be null and void and of no further force or effect notwithstanding any provision contained therein to the contrary including, without limitation, any provisions related to any
surviving obligations of the parties. 
  
 10.2
Nonsolicitation of Personnel. Neither party hereto shall, without the prior written consent to the other party, either directly or indirectly, alone or in conjunction with any other person or entity, solicit or attempt to solicit any
“key or material” employee, consultant, contractor or personnel of such other party to terminate, alter or lessen his or her affiliation with such other party at any time during the Term of this Agreement and for a period of one (1) year
thereafter. 
  
 ARTICLE 11 
 ARBITRATION OF DISPUTES 
  
 All disputes arising out of or in connection with the interpretation, application or enforcement of this Agreement shall be settled by final and binding
arbitration. Such arbitration shall be conducted in a mutually acceptable location of approximately equal geographic distance from the addresses of the parties first above written, pursuant to the commercial arbitration rules of the American
Arbitration Association in effect at the time the arbitration is commenced. The decision of the arbitrators, which may include interest, shall be final and binding on the parties hereto and may be entered and enforced in any court of competent
jurisdiction by any party. The arbitration shall be pursued and brought to conclusion as rapidly as possible. The prevailing party in the arbitration proceeding shall be awarded reasonable attorneys’ fees, expert witness costs and expenses, and
all other costs and expenses incurred in connection with such proceeding, unless the arbitrators shall for good cause determine otherwise. 
  

 -10- 

  
 ARTICLE 12 

 NOTICES 
  
 12.1 Delivery. All notices, consents, requests and other communications hereunder shall be in writing and shall be sent by hand delivery, by
certified or registered mail (return-receipt requested), or by a recognized national overnight courier service as set forth below: 
  

			
	If to Mikart:	  	Mikart, Inc.
	 	  	1750 Chattahoochee Avenue
	 	  	Atlanta, Georgia 30318
	 	  	Attention: Miguel I. Arteche, Chairman and CEO
		
	If to TEAMM:	  	TEAMM Pharmaceuticals, Inc.
	 	  	Suite 110
	 	  	 3000 Aerial Center Parkway
 Morrisville, NC
27560
 Attention: Martin G. Baum, President & Chief Executive Officer

  
 12.2 Effective
Time. Notices delivered pursuant hereto shall be deemed given: (a) at the time delivered, if personally delivered; (b) at the time received, if mailed; and (c) one (1) business day after timely delivery to the courier, if by overnight
courier service. 
  
 12.3 Changes. Either party
hereto may change the address to which notice is to be sent by written notice to the other party in accordance with the provisions of this Article 12. 
  
 ARTICLE 13 
 MISCELLANEOUS

  
 13.1 Severability. If any provision of
this Agreement is held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired, and the parties shall use their best efforts to substitute a valid,
legal and enforceable provision, which, insofar as practical, implements the purpose of this Agreement. 
  
 13.2 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which
together shall be deemed one and the same instrument. 
  
 13.3
Governing Law. This Agreement shall be governed by, and any matter or dispute arising out of this Agreement shall be determined by, the laws of the State of Georgia, 

  

 -11- 

 
interpretation of this Agreement. All personal pronouns used in this Agreement shall include the other genders, whether used in the masculine, feminine or
neuter gender, and the singular shall include the plural and vice versa, whenever and as often as may be appropriate. 
  
 13.5 Entire Agreement. This Agreement represents the entire agreement of the parties with respect to its subject matter. Any
and all prior discussions or agreements with respect hereto are merged into and superseded by the terms of this Agreement. This Agreement may be modified or amended only in writing signed by both parties which expressly refers to this Agreement and
states an intention to modify or amend it. No such amendment or modification shall be effected by use of any purchase order, acknowledgment, invoice or other form of either party and in the event of conflict between the terms of this Agreement and
any such form, the terms of this Agreement shall control. 
  
 13.6 Notices. Any notice or payment required or permitted hereunder shall be in writing and sent by certified mail, overnight express, or personally delivered, addressed to the party to receive the notice as set
out below. 
  
 13.7 No
Assignment. Neither party hereto may assign this Agreement, in whole or in part, without the prior written consent of the other party (which consent shall not be unreasonably withheld or delayed), and any attempted assignment not in
accordance herewith shall be null and void and of no force or effect. 
  
 13.8 Binding Effect. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors, heirs, representatives and permitted
assigns. 
  
 13.9 Interpretation.
This Agreement was fully negotiated by both parties hereto and shall not be construed more strongly against either party hereto regardless of which party is responsible for its preparation. 
  
 13.10 No Consequential Damages. Neither party to
this Agreement shall have any liability to the other party for any consequential or indirect damages arising out of any breach of this Agreement, including, without limitation, loss of profit, loss of use or business stoppage. 
  
 13.11 Further Assurances. Upon the reasonable
request of the other party, each party hereto agrees to take any and all actions necessary or appropriate to give effect to the terms set forth in this Agreement. 
  

 -12- 

 IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives to
execute this Agreement as of the day and year first above written. 
  

			
	“Mikart”
	
	MIKART, INC.
		
	By:	 	 /s/ Miguel I. Arteche

	 	 	 Miguel I. Arteche, Chairman and CEO

	
	“TEAMM”
	
	TEAMM PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Martin G. Baum

	 	 	 Martin G. Baum, President & Chief Executive Officer

  

 -13- 

  
 Exhibit A 

 
 MIKART, INC. 
 FINISHED PRODUCT SPECIFICATIONS/SUBMISSION FORM 
  
  
 [*]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]